Back to top
more

Geron (GERN)

(Real Time Quote from BATS)

$3.79 USD

3.79
1,205,342

-0.11 (-2.82%)

Updated May 17, 2024 10:52 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What's in the Cards for Geron (GERN) This Earnings Season?

by Zacks Equity Research

In a major setback to Geron (GERN), J&J terminates collaboration for development of its sole pipeline candidate, imetelstat. Investor focus to remain on path forward for imetelstat.

Geron (GERN) Stock Moves -0.58%: What You Should Know

by Zacks Equity Research

In the latest trading session, Geron (GERN) closed at $1.72, marking a -0.58% move from the previous day.

Do Options Traders Know Something About Geron (GERN) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.

Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs

by Zacks Equity Research

The biotech sector grabs headlines this week with FDA approvals plus licensing and acquisition pacts.

    Geron's Stock Plunges as J&J Ends Imetelstat Collaboration

    by Zacks Equity Research

    Geron (GERN) announces termination of collaboration with J&J for development of its sole pipeline candidate, imetelstat.

      Options Traders Expect Huge Moves in Geron (GERN) Stock

      by Zacks Equity Research

      Geron (GERN) needs investors to pay close attention to the stock based on moves in the options market lately.

        Geron Stock Up More Than 200% in 2018 So Far: Here's Why

        by Zacks Equity Research

        Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in Janssen sponsored studies.

          Why Is Geron (GERN) Up 58% Since Last Earnings Report?

          by Zacks Equity Research

          Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

            Geron's Growth Depends on Continuation of Imetelstat Studies

            by Zacks Equity Research

            Investors continue to focus on development of Geron's (GERN) sole pipeline candidate, imetelstat. However, competition is rife with other companies developing treatments for similar indications.

              Implied Volatility Surging for Geron (GERN) Stock Options

              by Zacks Equity Research

              Geron (GERN) needs investors to pay close attention to the stock based on moves in the options market lately.

                Geron (GERN) Q2 Loss In Line, Revenues Up Y/Y, Shares Down

                by Zacks Equity Research

                Geron (GERN) meets earnings estimates on higher sales in the second quarter. Operating expenses however increase year over year.

                  Are Options Traders Betting on a Big Move in Geron (GERN) Stock?

                  by Zacks Equity Research

                  Investors in Geron (GERN) need to pay close attention to the stock based on moves in the options market lately.

                    Implied Volatility Surging for Geron (GERN) Stock Options

                    by Zacks Equity Research

                    Geron (GERN) needs investors to pay close attention to the stock based on moves in the options market lately.

                      Is Geron (GERN) Outperforming Other Medical Stocks This Year?

                      by Zacks Equity Research

                      Is Geron Corporation (GERN) Outperforming Other Medical Stocks This Year?

                        Geron (GERN) Q1 Loss Narrows Y/Y, Revenues Fall, Shares Down

                        by Zacks Equity Research

                        Geron (GERN) beats earnings but on lower sales in Q1. Operating expenses were lower year over year.

                          What's in the Cards for Geron (GERN) This Earnings Season?

                          by Zacks Equity Research

                          With no approved product in Geron's (GERN) portfolio, investor focus continues to remain on its sole pipeline candidate, imetelstat, ahead of the first-quarter earnings release.

                            Is Geron Corporation (GERN) Stock Outpacing Its Medical Peers This Year?

                            by Zacks Equity Research

                            Is Geron Corporation (GERN) Outperforming Other Medical Stocks This Year?

                              Why Is Geron (GERN) Up 10.6% Since Its Last Earnings Report?

                              by Zacks Equity Research

                              Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                Here's Why Geron Stock Surged More Than 90% in 6 Months

                                by Zacks Equity Research

                                Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.

                                  Geron (GERN) Q4 Loss Flat Y/Y, Revenues Surge, Shares Up

                                  by Zacks Equity Research

                                  Geron (GERN) misses earnings and sales estimates in Q4. However, revenues almost double year over year. Imetelstat remains in focus.

                                    Geron (GERN) in Focus: Stock Moves 10.8% Higher

                                    by Zacks Equity Research

                                    Geron (GERN) was a big mover last session, as the company saw its shares rise nearly 11% on the day.

                                      J&J's (JNJ) Erdafitinib Gets Breakthrough Therapy Status

                                      by Zacks Equity Research

                                      The breakthrough therapy designation for J&J's (JNJ) erdafitinib was based on efficacy findings from a phase II study, evaluating it in advanced urothelial cancer.

                                        What's in the Cards for Geron (GERN) This Earnings Season?

                                        by Zacks Equity Research

                                        With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q4 release.

                                          Geron (GERN) Q3 Loss Narrower Than Expected, Sales Miss

                                          by Zacks Equity Research

                                          Geron's (GERN) loss per share in the third quarter was narrower than expected. However, revenues missed estimates. Imetelstat remains in focus.

                                            Geron (GERN) in Focus: Stock Moves 9.2% Higher

                                            by Zacks Equity Research

                                            Geron (GERN) saw its shares rise over 9% on the day after the company received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its experimental blood-cancer medicine, imetelstat.